← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksFEMYPrice Target
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

FEMY logoFemasys Inc. (FEMY) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential

Current Price
$0.43
Market reference
Price Target
—
— Upside
Target Range
— — —
Analyst Rating
—
0 analysts
Forward P/E—
Trailing P/E-0.9x
Forward PEG—
Implied Growth—
Median Target—
Analyst Spread—

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$0.43
Consensus—
High—
Low—
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—

Analyst Ratings

No analyst coverage available for FEMY

Coverage appears once Wall Street estimates are published.

FEMY Price Target Analysis

Updated May 8, 2026

As of May 8, 2026, Femasys Inc. (FEMY) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $13M.

Analyst price targets range from a low of N/A to a high of N/A.

The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.

From a valuation perspective, FEMY trades at a trailing P/E of -0.9x.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+21.9%
Avg Forward P/E41.7x
Peers with Coverage6 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
CODA logoCODACoda Octopus Group, Inc.$136M$12.11$14.00+15.6%Buy22.8x1
BLFS logoBLFSBioLife Solutions, Inc.$1.1B$22.04$33.00+49.7%Buy143.8x17
XWEL logoXWELXWELL, Inc.$8M$1.49—————
HOLO logoHOLOMicroCloud Hologram Inc.$3M$1.75—————
SSKN logoSSKNSTRATA Skin Sciences, Inc.$6M$0.15—————
TELA logoTELATELA Bio, Inc.$41M$1.02—————
NXRT logoNXRTNexPoint Residential Trust, Inc.$760M$29.95$27.00-9.8%Hold—10
HOLX logoHOLXHologic, Inc.$17.0B$76.01$79.00+3.9%Hold17.2x42
BDX logoBDXBecton, Dickinson and Company$54.1B$149.44$172.85+15.7%Hold11.9x34
COO logoCOOThe Cooper Companies, Inc.$11.8B$60.00$93.86+56.4%Buy13.0x24

Upside Potential Comparison

COO logoCOO
+56.4%
BLFS logoBLFS
+49.7%
BDX logoBDX
+15.7%
CODA logoCODA
+15.6%
HOLX logoHOLX
+3.9%
NXRT logoNXRT
-9.8%

See FEMY's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is FEMY Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare FEMY vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

FEMY — Frequently Asked Questions

Quick answers to the most common questions about buying FEMY stock.

What is the FEMY stock price target for 2026?

The consensus price target for FEMY is $N/A, close to the current price of $0.4299 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.

Is FEMY a buy, sell, or hold?

FEMY has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.

Is FEMY stock overvalued or undervalued?

FEMY's current price is $0.4299 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.

How high can FEMY stock go?

The most bullish Wall Street analyst has a price target of $N/A for FEMY, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover FEMY stock?

FEMY is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the FEMY stock forecast?

The 12-month FEMY stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".

Should I buy FEMY stock?

FEMY appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do FEMY price targets vary so much?

FEMY analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.